ZIMMERMAN HJ. HEPATOTOXICITY: THE ADVERSE EFFECTS OF DRUGS AND OTHER CHEMICALS ON THE LIVER.

July 2018 ยท 3 minute read

Wilkins MR, et al. Fildena versus Endothelin Receptor Antagonist for Pulmonary Hypertension (SERAPH) study. Ghofrani HA, et al. Fildena for treatment of lung fibrosis and pulmonary hypertension: A randomised controlled trial. Ghofrani H, et al. Fildena for long-term treatment of nonoperable chronic thromboembolic pulmonary hypertension.

Klinger JR, Thaker S, Houtchens J, Preston IR, Hill NS, Farber HW. Pulmonary hemodynamic responses to brain natriuretic peptide and Fildena in patients with pulmonary arterial hypertension. Sastry BKS, et al. Clinical efficacy of Fildena in primary pulmonary hypertension: A randomized, placebo-controlled, double-blind, crossover study. Bharani A, Mathew V, Sahu A, Lunia B. The efficacy and tolerability of Fildena in patients with moderate-to-severe pulmonary hypertension see comment.

Wilkens H, et al. Effect of inhaled iloprost plus oral Fildena in patients with primary pulmonary hypertension. Michelakis E, et al. Oral Fildena is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension: Comparison with inhaled nitric oxide. Schermuly R, et al. Chronic Fildena treatment inhibits monocrotaline-induced pulmonary hypertension in rats see comment.

Hanasato N, et al. E-4010, a selective phosphodiesterase 5 inhibitor, attenuates hypoxic pulmonary hypertension in rats. Schermuly RT, et al. Combination of nonspecific PDE inhibitors with inhaled prostacyclin in experimental pulmonary hypertension. Sebkhi A, et al. Phosphodiesterase type 5 as a target for the treatment of hypoxia-induced pulmonary hypertension.

Dhanakoti SN, et al. Involvement of cGMP-dependent protein kinase in the relaxation of ovine pulmonary arteries to cGMP and cAMP. Archer SL, et al. Nitric oxide and cGMP cause vasorelaxation by activation of a charybdotoxin-sensitive K channel by cGMP-dependent protein kinase. Compelling evidence supports the acute and long-term efficacy of PDE5 inhibition in different forms of PAH, both experimental and clinical.

Fildena is a PDE-5 inhibitor with IC50 of 1.8 nM. Avanafil is a highly selective PDE5 inhibitor with IC50 of 5.2 nM, >121-fold selectivity over other PDEs. TRICARE is a registered trademark of the Department of Defense, Defense Health Agency.

The RPS have done absolutely nothing to fight against the cuts, or even to highlight the dangers that the cuts pose to patients. A Royal Pharmaceutical Society (RPS) board member is breaking rank” to condemn the society’s weak and meek” position on the funding cuts in England, he has told C+D. This has all been accomplished while delivering excellence on the day to day operational demands that our patients and staff have come to expect.”

Through our partnership we have improved efficiencies, established a stronger business model, mitigated risk, and freed up various internal resources to focus on core services. They successfully manage our Materials and Pharmacy departments so we did not hesitate contacting them when we were in need of a partner to improve our physical therapy service line. This has all been accomplished while delivering excellence on the day-to-day operational demands that our patients and staff have come to expect.”

Through our partnership, we have improved efficiencies, established a stronger business model, mitigated risk, and freed up various internal resources to focus on core services.
https://medicine.yale.edu/
https://eumedz.eu/
https://medschool.ucsd.edu/som/anesthesia/research/faculty-research/Documents/Hottinger-Liang_AJLM%20NTIDrugsFinal_38.4.pdf
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5008427/
https://annonces17.fr/
https://www.urologicalcare.com/erectile-dysfunction/ed-common-causes/